Short‐Course Subcutaneous Immunotherapy With Mannan‐Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements
Study limitation reported by the research below: “The primary CSMS effect size (0.31) was below the proposed minimally clinically important difference threshold of 0.5; clinical significance of the benefit should be interpreted cautiously.”